Effects of torcetrapib in patients at high risk for coronary events

New England Journal of Medicine

Volumn 357, Issue 21, 2007, Pages 2109-2122

  Barter, Philip J ^a   Caulfield, Mark ^b   Eriksson, Mats ^c   Grundy, Scott M ^d   Kastelein, John J P ^e   Komajda, Michel ^f   Lopez Sendon, Jose ^g   Mosca, Lori ^h   Tardif, Jean Claude ⁱ   Waters, David D ^j   Shear, Charles L ^k   Revkin, James H ^k   Buhr, Kevin A ^l   Fisher, Marian R ^l   Tall, Alan R ^m   Brewer, Bryan ⁿ  

^a HEART RESEARCH INSTITUTE   (Australia)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f SORBONNE UNIVERSITÉ   (France)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h Och Spine at New York Presbyterian Hospitals   (United States)

ⁱ MONTREAL HEART INSTITUTE   (Canada)

^j SAN FRANCISCO GENERAL HOSPITAL   (United States)

^k PFIZER INC   (United States)

^l UNIVERSITY OF WISCONSIN MADISON   (United States)

^m NewYork Presbyterian Hospital   (United States)

ⁿ Medstar Institute   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ATORVASTATIN; BICARBONATE; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POTASSIUM; SODIUM; TORCETRAPIB;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; BICARBONATE BLOOD LEVEL; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HEART DEATH; HEART INFARCTION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORBIDITY; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SODIUM BLOOD LEVEL; STROKE; SYSTOLIC BLOOD PRESSURE; TREATMENT FAILURE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 36348975228     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0706628     Document Type: Article

References (16)

1. Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discovery 2005;4:193-205.
2. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989;79:8-15.
3. Chapman MJ. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Ther 2006;111:893-908.
4. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-10.
5. Hirano K, Yamashita S, Matsuzawa Y. Pros and cons of inhibiting cholesteryl ester transfer protein. Curr Opin Lipidol 2000;11:589-96.
6. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23:160-7.
7. Barter PJ, Kastelein JP. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J Am Coll Cardiol 2006;47:492-9.
8. Morehouse LA, Sugarman ED, Bourassa P-A, et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in NZW rabbits. J Lipid Res 2007;48:1263-72.
9. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004;350:1505-15.
10. McKenney JM, Davidson MH, Shear CL, Revkin JH. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol 2006;48:1782-90.
11. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304-16. [Erratum, N Engl J Med 2007;357:835.]
12. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620-30.
13. Bots ML, Visseren FLJ, Evans GW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007;370:153-60.
14. In interests of patient safety, Pfizer stops all torcetrapib clinical trials; company has notified FDA and is in the process of notifying all clinical investigators and other regulatory authorities. Pfizer news release, December 2, 2006. (Accessed October 30, 2007, at http://www.fda.gov/bbs/topics/NEWS/2006/ NEW01514.html.)
15. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-70.
16. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 2007;298:786-98. [Erratum, JAMA 2007;298:1516.]